Changes in the factors associated with the renal prognosis during 12 months before and after administration of luseogliflozin in patients with type 2 diabetes
Not Applicable
- Conditions
- diabetes mellitus
- Registration Number
- JPRN-UMIN000041193
- Lead Sponsor
- Department of Diabetes, Metabolism and Kidney Disease,Edogawa Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 238
Inclusion Criteria
Not provided
Exclusion Criteria
Subjects with replacement from other SGLT2 inhibitors or GLP-1 receptor antagonists, those with observation period less than 12 months, those with change of diuretics or anti-hypertensive agents during the observation period and those with add-on of GLP-1 receptor antagonists during the observation period
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Changes in eGFR during 12 months before and after administration of luseogliflozin
- Secondary Outcome Measures
Name Time Method Changes in urinary protein excretion, urinary albumin excretion and urinary L-FABP during 12 months after administration of luseogliflozin